Novavax, Inc. (NASDAQ:NVAX – Get Free Report) Director James F. Young sold 7,500 shares of the firm’s stock in a transaction on Tuesday, June 18th. The shares were sold at an average price of $13.72, for a total transaction of $102,900.00. Following the transaction, the director now directly owns 69,260 shares of the company’s stock, valued at approximately $950,247.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Novavax Stock Down 6.4 %
NVAX stock opened at $13.11 on Thursday. The stock’s 50 day simple moving average is $11.63 and its 200 day simple moving average is $7.11. Novavax, Inc. has a fifty-two week low of $3.53 and a fifty-two week high of $23.86.
Novavax (NASDAQ:NVAX – Get Free Report) last issued its earnings results on Friday, May 10th. The biopharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.04) by ($0.01). The company had revenue of $93.90 million during the quarter, compared to the consensus estimate of $71.32 million. The firm’s quarterly revenue was up 15.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($3.41) EPS. On average, sell-side analysts expect that Novavax, Inc. will post 0.49 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Analysts Set New Price Targets
A number of research firms recently commented on NVAX. Bank of America lifted their price objective on Novavax from $12.00 to $18.00 and gave the stock a “neutral” rating in a research note on Friday, June 14th. JPMorgan Chase & Co. upgraded shares of Novavax from an “underweight” rating to a “neutral” rating in a research report on Friday, May 10th. B. Riley lifted their target price on shares of Novavax from $11.00 to $29.00 and gave the stock a “buy” rating in a research note on Thursday, May 23rd. HC Wainwright reaffirmed a “buy” rating and set a $19.00 price target on shares of Novavax in a research report on Monday, May 13th. Finally, TD Cowen lifted their price objective on Novavax from $5.00 to $10.00 and gave the stock a “hold” rating in a research report on Monday, May 13th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, Novavax presently has a consensus rating of “Hold” and an average target price of $19.00.
Get Our Latest Stock Report on Novavax
About Novavax
Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.
Featured Articles
- Five stocks we like better than Novavax
- What Are the FAANG Stocks and Are They Good Investments?
- Stock Impact: McDonald’s Price War with Starbucks, Wendy’s
- What is Insider Trading? What You Can Learn from Insider Trading
- General Mills Q4 Sales Miss Expectations, Triggering Stock Drop
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Enovix Stock Rises 35% in Short-Squeeze: This Rally Has Legs
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.